152 related articles for article (PubMed ID: 15942482)
1. Radioactive iodine therapy for malignant and benign thyroid disease: a Canadian national survey of physician practice.
Demeter S; Leslie WD; Levin DP
Nucl Med Commun; 2005 Jul; 26(7):613-21. PubMed ID: 15942482
[TBL] [Abstract][Full Text] [Related]
2. Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners.
Greenlee C; Burmeister LA; Butler RS; Edinboro CH; Morrison SM; Milas M;
Thyroid; 2011 Feb; 21(2):151-60. PubMed ID: 21275765
[TBL] [Abstract][Full Text] [Related]
3. Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey.
Sawka AM; Goldstein DP; Thabane L; Brierley JD; Tsang RW; Rotstein L; Kamalanathan S; Zhao B; Gafni A; Straus S; Ezzat S
Endocr Pract; 2008 Mar; 14(2):175-84. PubMed ID: 18308655
[TBL] [Abstract][Full Text] [Related]
4. Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States.
Sawka AM; Rotstein L; Brierley JD; Tsang RW; Thabane L; Gafni A; Straus S; Kamalanathan S; Zhao B; Goldstein DP; Rambaldini G; Ezzat S
Thyroid; 2007 Dec; 17(12):1235-42. PubMed ID: 17988197
[TBL] [Abstract][Full Text] [Related]
5. The relationship between extent of thyroid cancer surgery and use of radioactive iodine.
Haymart MR; Banerjee M; Yang D; Stewart AK; Doherty GM; Koenig RJ; Griggs JJ
Ann Surg; 2013 Aug; 258(2):354-8. PubMed ID: 23567930
[TBL] [Abstract][Full Text] [Related]
6. Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer.
Boucher A; Ezzat S; Hotte S; Rachinsky I; Rajaraman M; Ruether D; Wiseman SM; Brierley J; Ho C; Krzyzanowska M; Lamond N; Massicotte MH; Joseph S; Herscovitch K; Sikora L; Winquist E
Oral Oncol; 2021 Oct; 121():105477. PubMed ID: 34388408
[TBL] [Abstract][Full Text] [Related]
7. [Is our approach to thyroid nodules and differentiated thyroid carcinoma in agreement with the American guideline and European consensus?].
Gómez Sáez JM;
Endocrinol Nutr; 2010 Oct; 57(8):357-63. PubMed ID: 20685184
[TBL] [Abstract][Full Text] [Related]
8. Factors that influence radioactive iodine use for thyroid cancer.
Papaleontiou M; Banerjee M; Yang D; Sisson JC; Koenig RJ; Haymart MR
Thyroid; 2013 Feb; 23(2):219-24. PubMed ID: 23134514
[TBL] [Abstract][Full Text] [Related]
9. Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey.
Jabin Z; Kwon SY; Bom HS; Lin Y; Yang K; Inaki A; Dewi AR; Al-Ibraheem AN; Balooshi BA; San Luis TOL;
Nucl Med Commun; 2018 Apr; 39(4):283-289. PubMed ID: 29381585
[TBL] [Abstract][Full Text] [Related]
10. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm.
Roman BR; Feingold JH; Patel SG; Shaha AR; Shah JP; Tuttle RM; Epstein AJ
Thyroid; 2014 Oct; 24(10):1549-50. PubMed ID: 25065817
[No Abstract] [Full Text] [Related]
11. Patterns of Practice in Canadian Radiation Treatment Centres: Results of a National Survey.
Giddings A; Nica L; French J; Davis CA; Smoke M; Bolderston A
J Med Imaging Radiat Sci; 2018 Mar; 49(1):23-30. PubMed ID: 30479283
[TBL] [Abstract][Full Text] [Related]
12. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
13. Use of radioactive iodine for thyroid cancer.
Haymart MR; Banerjee M; Stewart AK; Koenig RJ; Birkmeyer JD; Griggs JJ
JAMA; 2011 Aug; 306(7):721-8. PubMed ID: 21846853
[TBL] [Abstract][Full Text] [Related]
14. Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient
Gomes-Lima CJ; Wu D; Kharazi PH; Khojekar GJ; Ringel MD; Vetter RJ; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2017 Dec; 27(12):1558-1565. PubMed ID: 29132255
[TBL] [Abstract][Full Text] [Related]
15. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
Sneed RC; May WL; Stencel C
Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices.
Bernard D; Desruet MD; Wolf M; Roux J; Boin C; Mazet R; Gallazzini C; Calizzano A; Vuillez JP; Allenet B; Fagret D
Ann Endocrinol (Paris); 2014 Sep; 75(4):241-6. PubMed ID: 25156133
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy after treatment for breast cancer: physicians' attitudes towards randomized trials.
Del Giudice ME; Sawka CA; Pritchard KI; Llewellyn-Thomas HA; Trudeau ME; Lewis JE; Franssen E
Breast Cancer Res Treat; 2003 May; 79(2):213-23. PubMed ID: 12825856
[TBL] [Abstract][Full Text] [Related]
18. Variation in the management of thyroid cancer.
Haymart MR; Banerjee M; Yang D; Stewart AK; Sisson JC; Koenig RJ; Doherty GM; Griggs JJ
J Clin Endocrinol Metab; 2013 May; 98(5):2001-8. PubMed ID: 23539722
[TBL] [Abstract][Full Text] [Related]
19. Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule.
Walsh JP; Ryan SA; Lisewski D; Alhamoudi MZ; Brown S; Bennedbaek FN; Hegedüs L
Clin Endocrinol (Oxf); 2007 Jun; 66(6):844-53. PubMed ID: 17437521
[TBL] [Abstract][Full Text] [Related]
20. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma.
Chae AW; Martinez SR
Am Surg; 2018 May; 84(5):637-643. PubMed ID: 29966562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
